Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS (GLUT-HEP)

Trial Profile

Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS (GLUT-HEP)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 May 2015

At a glance

  • Drugs Triheptanoin (Primary)
  • Indications De Vivo disease
  • Focus Therapeutic Use
  • Acronyms GLUT-HEP
  • Most Recent Events

    • 30 Apr 2015 Planned End Date changed from 1 Nov 2014 to 1 Apr 2018 as reported by ClinicalTrials.gov record.
    • 30 Apr 2015 Planned primary completion date changed from 1 Nov 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.
    • 22 Apr 2015 According to Ultragenyx media release, the company is planning to initiate a confirmatory study based on the results of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top